Cannabidiol Shows Promise Against Sun Damage, But It Is No Sunscreen Yet

Cannabidiol, the non-psychoactive compound extracted from Cannabis sativa, has become one of the most fashionable ingredients in skincare, appearing in everything from facial serums to body lotions. Now a narrative review published in the Archives of Dermatological Research has taken a hard look at whether the molecule could earn a place in something far more demanding: sunscreen. The verdict from a team led by George Papadeas of Ohio University Heritage College of Osteopathic Medicine and Robert Dellavalle of the University of Minnesota is nuanced. CBD shows genuine, mechanistically interesting effects against the cellular fallout of ultraviolet radiation, but it has never been shown to filter UV light in any meaningful way, and no finished sunscreen containing CBD has demonstrated improved performance.

The researchers surveyed peer-reviewed literature published through mid-2024, searching PubMed, Google Scholar, ScienceDirect and Wiley Online Library for studies combining cannabidiol with terms covering sunscreens, antioxidants, inflammation, UV radiation and skin biology. From that search, 19 studies made the final cut: four review articles, nine in vitro experiments, three animal studies, one human clinical trial and two mixed-method investigations. The authors are candid about the limits of their approach. Because this was a narrative review rather than a systematic one, they did not apply PRISMA methodology or formal risk-of-bias assessment, and they acknowledge the search may have missed relevant work, particularly non-English publications.

The most striking findings concern CBD’s antioxidant chemistry. Structurally, the molecule shares features with vitamins E and C: phenolic hydroxyl groups attached to aromatic rings that can donate hydrogen atoms to reactive oxygen species and free radicals, interrupting the chain reactions that damage lipids, proteins and DNA. CBD is also highly lipophilic, allowing it to accumulate in cell membranes and stabilize them in a manner reminiscent of vitamin E. In rat experiments, chronic UVA and UVB exposure distorted keratinocyte membrane phospholipid metabolism, and topical CBD partially reversed those changes, downregulating harmful lysophosphatidylcholines and phospholipase A2 activity while upregulating protective phosphatidylethanolamines and phosphatidylserines. In human keratinocytes stressed with hydrogen peroxide or UVB, CBD reduced malondialdehyde and 4-hydroxynonenal, two well-established markers of lipid peroxidation, and modulated proteostasis networks governing protein folding and redox balance in ways that increased cell survival.

Beyond these direct chemical effects, CBD appears to manipulate the skin’s own antioxidant machinery. The review highlights its interaction with Nrf2, a redox-sensitive transcription factor often described as the master regulator of cytoprotective gene expression. Under normal conditions Nrf2 is held inactive by its nemesis Keap1, which tags it for destruction by the proteasome. Oxidative stress disrupts this pairing, freeing Nrf2 to enter the nucleus and switch on genes encoding superoxide dismutase, glutathione peroxidase and heme oxygenase 1. Intriguingly, keratinocyte studies suggest CBD is only a weak Nrf2 activator but a strong inhibitor of BACH1, a transcriptional repressor that works alongside Nrf2 to control heme oxygenase 1. This positions CBD as an Nrf2-independent booster of HMOX1 expression, encouraging keratinocyte differentiation and cytokeratin production, processes critical to maintaining a skin barrier that resists UV-induced DNA damage.

The anti-inflammatory story runs through a different set of molecular switches. CBD appears to be a major inhibitor of NFκB signaling, the central hub of the inflammatory response. Normally locked in the cytoplasm by its inhibitor IκB, NFκB is released when pro-inflammatory signals such as tumor necrosis factor alpha trigger IκB’s degradation, allowing the transcription factor to activate genes for cytokines, chemokines and adhesion molecules. UV irradiation drives inflammation through exactly this pathway, and in three-dimensional human keratinocyte cultures CBD counteracted it, restoring IκB levels and suppressing NFκB. CBD also dampened the NLRP3 inflammasome and the pro-inflammatory protein PGAM5, while full-spectrum CBD extract showed high-affinity inhibition of NLRP3 and TGF-β1 responses. In human skin fibroblasts, CBD elevated PPARγ, a nuclear receptor that represses inflammatory pathways, and in an acne study it significantly suppressed TNF-α, IL-1β and IL-6 in human sebocytes.

The endocannabinoid system adds yet another layer. CB2 receptors, found in immune and peripheral tissues including skin, can restrain pro-inflammatory cytokine release, and CBD’s modulation of CB2, along with its desensitization of TRPV1 channels activated by oxidative stress and its activation of adenosine A2A receptors, may collectively calm overactive immune responses in UV-damaged skin. One study of patients with psoriasis, atopic dermatitis and scarring found that a CBD-enriched ointment improved disease severity, quality of life, skin hydration and elasticity with no adverse effects. The review also flags a fascinating effect on melanocytes: CBD can activate p38 and p42/44 MAPK signaling and independently upregulate MITF, tyrosinase and related proteins, enhancing melanogenesis, the production of the pigment that naturally scatters and absorbs UV radiation. This raises potential applications for hypopigmented disorders and hints at melanin-mediated photoprotection.

But here is where the enthusiasm must be tempered, and the review is refreshingly blunt about it. Spectral analyses show that CBD absorbs UV light predominantly between roughly 220 and 280 nanometers, a range overlapping UVC, which is filtered out by the atmosphere, and only minimally touching the UVB band that sunscreens must block. In one comparative study, CBD showed the strongest cytoprotection against UVA-associated injury while cannabinol performed best against UVB, but neither CBD nor its relatives demonstrated direct photoprotective absorption at the wavelengths that matter. The authors emphasize that the observed cytoprotective effects should not be interpreted as sunscreen activity. CBD’s benefits, if real, would be indirect, working beneath the filter layer to help skin cells survive whatever radiation gets through.

Safety questions also complicate the picture. Most systematic safety data come from oral CBD, where randomized trials have identified increased risks of diarrhea, somnolence, decreased appetite and abnormal liver function tests, though the hepatic and sedation signals were concentrated in high-dose childhood epilepsy studies using drugs like clobazam and valproate. CBD is metabolized by CYP450 liver enzymes and can be a potent dose-dependent inhibitor of their activity, a concern that depends heavily on how much of a topical dose actually reaches the bloodstream. Evidence on that front is mixed: in a 17-day study of 46 healthy adults, CBD was detectable in blood after repeated use of three of five commercial topical products, though concentrations were far below those from oral or inhaled use and no cognitive or physiological effects appeared. Topical tolerability data remain thin and formulation-dependent, with patch-testing studies showing selected CBD products were non-irritating and non-sensitizing in healthy adults, while a transdermal gel trial saw application-site dryness, pain and one case of irritant contact dermatitis.

There is one tantalizing human data point. A small pilot randomized trial of nanoparticle-encapsulated topical CBD, involving just 19 participants, found less erythema on treated skin after UVA irradiation, along with reductions in epidermal hyperplasia and cellular stress and aging markers. But the study measured no SPF and included no active sunscreen comparator, so it cannot speak to whether CBD would add anything to a real product. The review also raises a subtle photochemical concern: when CBD oxidizes, it can form the cannabinoid quinone HU-331, which absorbs UV near 270 and 409 nanometers and has shown topoisomerase-II inhibition and endothelial-cell apoptosis induction in non-skin experimental systems. CBD and its hydroxyquinone have also generated reactive oxygen species during mouse liver microsomal metabolism. None of this demonstrates phototoxicity in human skin, but it marks genuine toxicologic uncertainties that demand study before CBD rides around in a sun-exposed bottle.

The regulatory landscape adds a final layer of complexity. In the United States, sunscreens are regulated as over-the-counter drugs, and only zinc oxide and titanium dioxide currently meet the FDA’s Generally Recognized as Safe and Effective standard, while the 2022 Modernization of Cosmetics Regulation Act has tightened scrutiny of cosmetic ingredients, with new 2026 legislation targeting full-spectrum CBD products specifically. Any manufacturer hoping to add CBD to a sunscreen would face registration, human safety substantiation and adverse event surveillance requirements. The review’s bottom line is measured: CBD may eventually earn a role as an adjunctive, non-filter component of photoprotective skincare, but the evidence base, dominated by in vitro and rodent work with enormous variability in models and doses, is nowhere near supporting claims of sun protection. Until standardized SPF, stability, photostability and human safety testing say otherwise, your sunscreen’s active ingredients should remain the ones with proven track records.

Subject of Research: Preclinical evidence on cannabidiol's effects against ultraviolet-induced skin damage and its potential as a sunscreen additive

Article Title: Cannabidiol and ultraviolet-induced skin damage: a narrative review of preclinical evidence and translational considerations for sunscreen additive development

Article References: Papadeas, G. G., Szeto, M. D., Reed, M. J., Paul, A., Runion, T. M., Anderson, J., & Dellavalle, R. P. (2026). Cannabidiol and ultraviolet-induced skin damage: a narrative review of preclinical evidence and translational considerations for sunscreen additive development. Archives of Dermatological Research, 318(1), Article 430. https://doi.org/10.1007/s00403-026-04888-x

Image Credits: AI Generated

DOI: 10.1007/s00403-026-04888-x

Keywords: cannabidiol, CBD, sunscreen, UV radiation, photoprotection, skin cancer, antioxidant, anti-inflammatory, keratinocytes, melanocytes, Nrf2, dermatology